Table 3.
Characteristic | No. subjects | Spearman rho | P Value | Partial r | P Value |
---|---|---|---|---|---|
Fasting glucose (mg/dl) | 1490 | 0.07 | 0.001 | 0.07 | 0.02 |
HOMA-IR (U) | 1460 | 0.14 | <0.001 | 0.08 | 0.003 |
Systolic BP (mmHg) | 1786 | 0.04 | 0.11 | 0.05 | 0.08 |
Diastolic BP (mmHg) | 1786 | 0.08 | <0.001 | 0.08 | 0.003 |
ACR | 1723 | 0.04 | 0.11 | 0.04 | <0.10 |
GFR | 1788 | 0.00 | 0.88 | 0.01 | 0.63 |
Total cholesterol (mg/dl) | 1788 | 0.18 | <0.001 | 0.16 | <0.001 |
LDL cholesterol (mg/dl) | 1787 | 0.13 | <0.001 | 0.10 | <0.001 |
HDL cholesterol (mg/dl) | 1788 | 0.03 | 0.16 | 0.04 | 0.13 |
Triglycerides (mg/dl) | 1788 | 0.14 | <0.001 | 0.14 | <0.001 |
Total lipoprotein HDL particles (nmol/L) | 1712 | 0.22 | <0.001 | 0.21 | <0.001 |
Lipoprotein large HDL (nmol/L) | 1712 | −0.04 | 0.09 | −0.05 | 0.09 |
Lipoprotein medium HDL (nmol/L) | 1712 | 0.09 | <0.001 | 0.09 | 0.001 |
Lipoprotein small HDL (nmol/L) | 1712 | 0.17 | <0.001 | 0.18 | <0.001 |
HDL lipoprotein particle size (nm) | 1712 | −0.11 | <0.001 | −0.12 | <0.001 |
Plasma APOA1 (μM) | 1741 | 0.35 | <0.001 | 0.39 | <0.001 |
CRP (mg/L) | 1782 | 0.14 | <0.001 | 0.10 | <0.001 |
IL-6 (pg/ml) | 1664 | 0.07 | 0.004 | 0.05 | 0.04 |
IL-18 (mg/L) | 1188 | 0.06 | 0.04 | 0.07 | 0.01 |
IL1AP (ng/ml) | 1663 | 0.03 | 0.21 | 0.03 | 0.19 |
TNFR1A (ng/ml) | 1660 | −0.02 | 0.49 | −0.02 | 0.37 |
CXCL10 (ng/ml) | 1660 | 0.03 | 0.28 | 0.01 | 0.69 |
CD40 ligand (ng/ml) | 1495 | −0.05 | 0.06 | −0.05 | 0.09 |
Correlation coefficients were calculated for all black participants with available clinical phenotypes, lipid and cytokine data, and plasma APOL1 measurements. Partial Pearson correlation coefficient (r) was determined from linear regression models, adjusted for age, gender, BMI, and the number of APOL1 risk alleles, with plasma APOL1 levels as a predictor and each characteristic as the outcome. HOMA-IR, homeostasis model assessment of insulin resistance; CRP, C-reactive protein; CXCL, C-X-C motif ligand; CD40, cluster of differentiation 40.